Featured on Genetic Engineering and Biotechnology News: To Develop Coronavirus Treatment, Lilly Taps AbCellera Antibody Platform

“Within a week of receiving a blood sample from one of the first U.S. patients to recover from COVIDcampaign-pages/bispecifics/-19, AbCellera, a Canadian therapeutic antibody discovery company, put its rapid pandemic response platform to work, identifying more than 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoVcampaign-pages/cd3/campaign-pages/cd3/-2 antibodies reported to date.”

Read full coverage on Genetic Engineering and Biotechnology news.


Together we can make game-changing discoveries.